PACB vs. NAUT, AKYA, QTRX, HBIO, SEER, LAB, BNGO, CTKB, AXDX, and EYPT
Should you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include Nautilus Biotechnology (NAUT), Akoya Biosciences (AKYA), Quanterix (QTRX), Harvard Bioscience (HBIO), Seer (SEER), Standard BioTools (LAB), Bionano Genomics (BNGO), Cytek Biosciences (CTKB), Accelerate Diagnostics (AXDX), and EyePoint Pharmaceuticals (EYPT). These companies are all part of the "analytical instruments" industry.
Pacific Biosciences of California (NASDAQ:PACB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking.
In the previous week, Nautilus Biotechnology had 6 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 10 mentions for Nautilus Biotechnology and 4 mentions for Pacific Biosciences of California. Nautilus Biotechnology's average media sentiment score of 0.17 beat Pacific Biosciences of California's score of -0.20 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.
50.7% of Nautilus Biotechnology shares are held by institutional investors. 1.9% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 42.5% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Nautilus Biotechnology has lower revenue, but higher earnings than Pacific Biosciences of California. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.
Pacific Biosciences of California has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.
Pacific Biosciences of California received 442 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 67.73% of users gave Pacific Biosciences of California an outperform vote while only 16.67% of users gave Nautilus Biotechnology an outperform vote.
Pacific Biosciences of California currently has a consensus target price of $7.77, suggesting a potential upside of 345.43%. Nautilus Biotechnology has a consensus target price of $6.00, suggesting a potential upside of 115.83%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, equities analysts plainly believe Pacific Biosciences of California is more favorable than Nautilus Biotechnology.
Nautilus Biotechnology has a net margin of 0.00% compared to Pacific Biosciences of California's net margin of -152.97%. Nautilus Biotechnology's return on equity of -24.31% beat Pacific Biosciences of California's return on equity.
Summary
Pacific Biosciences of California beats Nautilus Biotechnology on 9 of the 17 factors compared between the two stocks.
Get Pacific Biosciences of California News Delivered to You Automatically
Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacific Biosciences of California Competitors List
Related Companies and Tools
